Login to Access Video or Poster Abstract: MP80-07
Sources of Funding: none

Introduction

Sex cord-gonadal stromal tumors (SCGS) of the testicle, primarily made up of Leydig cell and Sertoli cell tumors, are rare testicular neoplasms. Single institutional studies suggest that metastases are rare and survival excellent. We utilized the SEER database to characterize risks of metastasis in patients with SCGS tumors.

Methods

We interrogated the SEER database from 1973 to 2010 to identify all Leydig cell (code -86503) and Sertoli cell (code -86403) tumors among male patients. Data collected and analyzed included patient age and race; SEER stage including limited to primary site (Localized), the presence of disease in retroperitoneal lymph nodes (Regional) and distant metastases (Distant); as well as cancer-specific and overall survival.

Results

We identified 53 patients with Leydig cell tumors and 23 with Sertoli cell tumors. Sertoli cell tumors were fairly evenly distributed overall all age groups while Leydig cell tumors were concentrated among ages 30-59. Using SEER extent of disease, 79% were found to be Localized and 21% Distant on initial presentation with equal distribution among patients with Leydig and Sertoli cell tumors. Median survival of patients presenting with metastases was 27 months. Patients with apparently Localized disease had a 13% chance of developing metastases at a median of 17 months. Patients with SCGS tumors of the testicle whether localized or metastatic had a significantly poorer survival compared to patients with germ cell tumors.

Conclusions

This study represents the largest analysis of outcomes for patients with SCGS tumors. These neoplasms have a high risk of presenting with metastasis (20%) than previously recognized as as well as a significant risk (13%) of patients with Localized tumor developing a recurrence. Patients with metastatic SCGS tumors are at higher risk of dying from their disease than patients with metastatic germ cell neoplasms likely due to inherent resistance to radiation and chemotherapy.

Funding

none